Abstract: Necroptosis is a tightly regulated form of necrosis that requires the activation of receptor-interacting protein (RIP) kinases RIPK1 and RIPK3, as well as the RIPK3 substrate mixed lineage kinase domain-like protein (MLKL). Because of membrane rupture, necroptotic cells release damage-associated molecular patterns (DAMPs) that evoke immune responses. Necroptosis is emerging as an important cellular response in the modulation of cancer initiation, progression, and metastasis. Necroptosis of cancer cells is considered to be an immunogenic cell death capable of activating anti-tumor immunity. Necroptosis also participates in the promotion of myeloid cell-induced adaptive immune suppression and thus contributes to oncogenesis. In addition, necroptosis of endothelial cells and tumor cells is conducive to tumor metastasis. In this review, we summarize the current knowledge of the complex role of necroptosis in cancer and discuss the potential of targeting necroptosis components for cancer therapies.
Introduction
Cell death is an essential aspect of development and tissue homeostasis in multicellular organisms. Apoptosis is a well-defined form of programmed cell death characterized by cell shrinkage, DNA condensation, and the formation of apoptotic bodies that are surrounded by an intact plasma membrane (Kerr et al., 1972) . Apoptosis is mediated by a family of cystine proteases termed caspases; the activity of these caspases is initiated by apoptotic stimuli via the activation of the death receptor pathway ("extrinsic pathway") or the mitochondrial pathway ("intrinsic pathway"). In contrast, necrosis has traditionally been viewed as an unregulated form of cell death characterized by morphological features including cell swelling and cell membrane rupture.
More recently, however, a regulated form of necrosis known as necroptosis (also "programmed necrosis") has been experimentally confirmed in detail. Necroptosis is controlled by receptor-interacting protein (RIP) kinases RIPK1, RIPK3, and mixed increasing evidence is accumulating that many cancer cells dampen necroptosis via epigenetic silencing of RIPK3 (Koo et al., 2015; Yang et al., 2017 ). In contrast to apoptosis, necroptosis results in the release of damage-associated molecular patterns (DAMPs), which further activate immune responses. The inflammatory implications of necroptosis enhance the immunogenicity of dying cancer cells and thereby increase anti-tumor immunity (Yatim et al., 2015; Aaes et al., 2016; Yang et al., 2016) . In addition to its suppressive role for tumorigenesis, necroptosis has been implicated in oncogenesis and in cancer metastasis. Viewed collectively, it is thus clear that necroptosis functions in complex ways in cancer initiation and development. This review focuses on recent advances in the understanding of the necroptosis machinery and its role in cancer initiation, development, metastasis, and treatment.
Discovery of necroptosis as a form of regulated necrosis
The tumor necrosis factor (TNF) superfamily of cytokines, including TNF-α, TNF-related apoptosisinducing ligand (TRAIL), and FasL/CD95L, is classic ligands for the activation of death receptors. Ligation of a death receptor (e.g. TNF receptor 1 (TNFR1)) by its ligand (e.g. TNF-α) triggers the extrinsic pathway of apoptosis. After the initial discovery that TNF-α is able to induce necrosis in certain cell lines in addition to apoptosis (Laster et al., 1988) , it was later found that TNF-induced necrosis is aggravated by inhibition of caspases in the presence of the chemical caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp (OMe)-fluoromethylketone (zVAD-fmk) and by the expression of a viral inhibitor of caspase-8, cytokine response modifier A (CrmA) (Vercammen et al., 1998) . Furthermore, more evidence suggests that apoptosis induced by TNF, TRAIL, and FasL/CD95L can be switched to necrosis when caspase activity is defective or inhibited.
In 2000, the protein kinase RIPK1 was identified as an essential regulator for necrotic cell death induced by TNF-α, TRAIL, or FasL/CD95L in a kinaseactivity-dependent manner (Holler et al., 2000) . It thus became clear that death receptor-initiated necrosis is tightly regulated by the kinase activity of RIPK1. This form of death receptor-initiated RIPK1-dependent necrosis was referred to as "programmed necrosis" (Chan et al., 2003) . In 2005, the term necroptosis was introduced to describe this regulated necrosis when necrostatin-1 (Nec-1) was identified as a specific chemical inhibitor of TNF-induced necrosis (Degterev et al., 2005) . Nec-1 was further found to inhibit the kinase activity of RIPK1 (Degterev et al., 2005) , and this inhibitor has been used extensively for the detection of necroptosis and for the evaluation of the in vivo basic biological significance of necroptosis (Yuan et al., 2019) .
In 2009, the kinase RIPK3 was found to regulate necroptosis (Cho et al., 2009; He et al., 2009; Zhang et al., 2009) . RIPK3 can associate with RIPK1 to form a protein complex (termed a necrosome) through the RIP homotypic interaction motif (RHIM) domains of both proteins (Sun et al., 2002) . Formation of the necrosome activates RIPK3, and this process leads to the phosphorylation of RIPK3. In 2012, MLKL was found to be a downstream substrate of RIPK3 and its phosphorylation by RIPK3 was confirmed to be essential for necroptosis execution (Sun et al., 2012; Zhao et al., 2012) . RIPK3-mediated phosphorylation of MLKL activates MLKL, leading to MLKL oligomerization and membrane translocation for the execution of necroptosis (Cai et al., 2014; Chen et al., 2014; Wang HY et al., 2014) .
Activation and execution of necroptosis
TNF-induced necroptosis is the best characterized pathway of necroptosis. Activation of TNFR1 by TNF-α is known to activate nuclear factor-κB (NF-κB) signaling, apoptosis, and necroptosis. Upon TNF-α ligation, TNFR1 is activated by inducing trimer formation. Activated TNFR1 receptors form a membrane signaling complex (called Complex I) by recruiting RIPK1, TNFR1-associated death domain protein (TRADD), cellular inhibitors of apoptosis (cIAPs), and TNFR-associated factor 2 (TRAF2) (Micheau and Tschopp, 2003) . In this complex, the E3 ubiquitin ligases, cIAP1 and cIAP2, induce RIPK1 ubiquitination (Bertrand et al., 2008; Haas et al., 2009) . RIPK1 further generates binding sites for NF-κB essential modifier (NEMO), which leads to further recruitment and activation of IκB kinase (IKK) α/β and promotes activation of the NF-κB signaling pathway (Gerlach et al., 2011; O'Donnell et al., 2012) .
Smac (Diabo) is a pro-apoptotic protein that can interact with inhibitor of apoptosis proteins (IAPs) to relieve their suppression of apoptosis. In the presence of Smac mimetic (a chemical compound that mimics Smac and induces the degradation of cIAPs), RIPK1 is deubiquitinated by cylindromatosis (CYLD) or A20 (Wertz et al., 2004; Wright et al., 2007; Hitomi et al., 2008) . RIPK1 is disassociated from Complex I and binds to Fas-associating protein with a novel death domain (FADD) and procaspase-8 to form Complex II in the cytoplasm (Micheau and Tschopp, 2003) . The precursor caspase-8 was cleaved into the active caspase-8, which further cleaves the downstream casepase-3/7, eventually leading to apoptosis. When caspase-8 activation is inhibited, RIPK1 interacts with RIPK3 to form a protein complex (necrosome) via their RHIM domains (Declercq et al., 2009 ), leading to activation and phosphorylation of both RIPK1 (human RIPK1 at Ser14/15 and Ser161/Ser166, and mouse RIPK1 at Lys45/Lys115) (Degterev et al., 2008; McQuade et al., 2013) and RIPK3 (human RIPK3 at Ser227 and mouse RIPK3 at Thr231/Ser232) (Sun et al., 2012; Chen et al., 2013) . Activated RIPK3 further phosphorylates the substrate MLKL, which is a pseudokinase. RIPK3-mediated phosphorylation of MLKL (human MLKL at Thr357/Ser358 and mouse MLKL at Ser345/Ser347) (Sun et al., 2012; Tanzer et al., 2015; Rodriguez et al., 2016 ) induces a conformational change of MLKL and leads to the activation of MLKL, which further forms oligomerization and translocates to the plasma membrane for the execution of necroptosis (Cai et al., 2014; Chen et al., 2014; Wang X et al., 2014) .
It has been shown that MLKL forms disulfide bond-dependent amyloid-like polymers to induce necroptosis (Liu et al., 2017) . Dovey et al. (2018) identified inositol phosphate (IP) kinases inositol polyphosphate multikinase (IPMK) and inositol 1,3,4-trisphosphate 5/6-kinase (ITPK1) as critical mediators of MLKL oligomerization and membrane localization. The highly phosphorylated IP molecule produced by these IP kinases, IP6, displaces the MLKL auto-inhibitory region, suggesting the requirement of a specific IP code in coordinating MLKL conformational changes to unleash necroptosis. Prior to membrane disruption, the activation of MLKL triggers the formation of plasma membrane bubbles, which display exposed phosphatidylserine Yoon et al., 2017; Zargarian et al., 2017) . Endosomal sorting complex required for transport-III (ESCRT-III) components are required for the formation of these membrane bubbles and for the release of phospho-MLKL-containing vesicles Yoon et al., 2017) . Inhibition of ESCRT components increased the sensitivity of cells to necroptosis. These results suggest that the ESCRT-III machinery provides protection against MLKL-mediated membrane damage by actively shedding broken membrane blebs. The necroptotic cells finally release cellular contents including DAMPs, which act as endogenous danger signals to elicit inflammatory responses.
Activation of RIPK3 is essential for the induction of necroptosis. The RHIM-dependent interaction of RIPK3 and RIPK1 is also required for IFN-induced necroptosis (Thapa et al., 2013) (Fig. 1) . In addition to interacting with RIPK1, RIPK3 can be activated by binding to other RHIM-containing proteins, including Toll/interleukin-1 receptor (TIR)-domain-containing adapter-inducing interferon-β (TRIF), DNA-dependent activator of interferon-regulatory factor (DAI, also known as ZBP1 or DLM1), and the viral protein ribonucleotide reductase large subunit (ICP6) (Wang X et al., 2014; Guo et al., 2015; Huang et al., 2015) ( Fig. 1 ). TLR3 and TLR4 are pathogen recognition receptors that can activate NF-κB activation and interferon regulatory factor 3 (IRF3)-mediated production of type I IFNs via the adaptor protein TRIF (Yamamoto et al., 2003) . TLR3 can be activated by double-stranded RNA (dsRNA) molecules such as poly(I:C), while TLR4 recognizes the lipopolysaccharide (LPS), a component of Gram-negative bacteria. In TLR3-or TLR4-induced necroptosis, TRIF is recruited to RIPK3 via their respective RHIM domains (He et al., 2011; Najjar et al., 2016) . Blockage of RIPK1 kinase activity by Nec-1 inhibits TLR4-induced macrophage necroptosis, while RIPK1 is not required for TLR3-induced necroptosis of mouse fibroblasts (He et al., 2011; Kaiser et al., 2013) , suggesting that RIPK3 can be activated by TRIF.
In response to infection of a mutant murine cytomegalovirus (MCMV) which lacks the viral RIHMcontaining protein viral inhibitor of RIP activation (vIRA) or influenza A virus, DAI activates RIPK3 and necroptosis of host cells independently of both RIPK1 and TRIF (Upton et al., 2010 (Upton et al., , 2012 Kuriakose et al., 2016; Najjar et al., 2016; Nogusa et al., 2016; Thapa et al., 2016) . In mouse cells infected with human herpes simplex virus (HSV)-1, mouse RIPK3 recruits the viral protein ICP6 and activates necroptosis. Together, these studies have established RIPK3 as a central molecular node for receiving necroptosisinitiating signals from multiple pathways via RIHMdependent interactions. Interestingly, RIPK3 can also be inactivated via RIHM-mediated interaction with the viral protein ICP6 in the natural host human cells (Huang et al., 2015; Yu et al., 2016) .
Necroptosis in tumor suppression

Defective necroptosis response in many cancer cells
Cell death of tumor cells is generally viewed as beneficial to cancer prevention and therapy, and evasion of apoptosis is considered a critical hallmark of cancer cells. It is therefore not surprising that cancer cells often have defects in their necroptosis responses. Downregulation of RIPK3 was observed in multiple types of human cancer samples, including breast cancers (Koo et al., 2015) , colorectal cancers (Feng et al., 2015) , and acute myeloid leukemia (AML) cells (Nugues et al., 2014) . Indeed, RIPK3 was found to be silenced in a variety of cancer cells. Treatment with a hypomethylating agent or knockdown of DNA methyltransferase 1 (DNMT1) or UHRF1 (ubiquitin-like, containing PHD and RING finger domains 1) promoted hypomethylation of the Ripk3 promoter, leading to the induction of RIPK3 expression in RIPK3-null cancer cells (Koo et al., 2015; Yang et al., 2017) . These results suggest that defects in RIPK3 expression in cancer cells may result from methylation of the Ripk3 promoter. Restored expression of RIPK3 by hypomethylating agents promoted the sensitivity to chemotherapeutics (Koo et al., 2015) . Hypomethylating agents have been used for clinical treatment of myelodysplastic syndrome and AML. Therefore, induction of RIPK3 expression by hypomethylating agents may provide an opportunity for the development of anticancer therapies for treating RIPK3-null cancer cells.
Moreover, it has been shown that low RIPK3 expression is associated with poor clinical outcomes in human colorectal cancer and that overexpression of RIPK3 can attenuate the migration and invasion of colorectal cancer cells (Feng et al., 2015) . The ectopic expression of RIPK3 in RIPK3-null cancer cells inhibited tumor growth (Koo et al., 2015; Yang et al., 2017) . These results suggest that the deletion or downregulation of RIPK3 in tumor cells favors cell survival and tumorigenesis. In addition, low expression of MLKL was shown to be associated with poor prognosis in patients with early-stage resected pancreatic adenocarcinoma (Colbert et al., 2013) , ovarian cancer (He et al., 2013) , and cervical cancer (Ruan et al., 2015) ; the mechanism leading to the downregulation of MLKL in these cancer samples has not been explored. These studies suggest that core necroptosis components RIPK3 and MLKL may serve as tumor suppressors.
Activation of necroptosis as a mechanism to overcome apoptosis resistance
Induction of cancer cell death is an important strategy for killing cancer cells. Cancer cells typically develop resistance to apoptosis via defective caspase activity owing to gene mutations or silencing. Since necroptosis tends to occur in the absence of caspase activation, it is conceivable that necroptosis is an alternative mode of cell death to overcome apoptosis resistance. This idea is strongly supported by the discovery that necroptosis is activated in caspase-8-deficient colorectal cancer cells in response to Smac mimetic and that necroptosis results in significant tumor regression in both a hereditary and a xenograft mouse model (He et al., 2017) (Fig. 2) . The Smac mimetic birinapant, in combination with the clinical caspase-8 inhibitor emricasan/IDN-6556, was shown to effectively trigger necroptosis of acute myelogenous leukemia (AML) cells, and this was found to prolong the survival of mice bearing MLL-AF9 or MLL-ENL birinapant-resistant AML cells (Brumatti et al., 2016) . Birinapant has been also shown to induce RIPK1-dependent apoptosis and necroptosis in patient-derived acute lymphoblastic leukemia (ALL) cells and to exhibit an anti-tumor effect on Smac mimetic-sensitive ALL in vivo (McComb et al., 2016) . Another Smac mimetic (BV6) was able to activate TNF-dependent necroptosis in patient-derived AML cells, although these cells were resistant to apoptosis (Safferthal et al., 2017) . Similarly, BV6 could trigger necroptosis in pancreatic carcinoma cells when caspase activation was blocked (Hannes et al., 2016) .
Additionally, the plant natural product shikonin was shown to induce cell death of MCF-7 that could be blocked by Nec-1 (Han et al., 2007) (Fig. 2) . Further studies have shown that shikonin upregulates the expression levels of RIPK1 and RIPK3 and induces the formation of the RIPK1/RIPK3 necrosome complex in multiple cancer cells (Fu et al., 2013; Park et al., 2013; Lu et al., 2017) . A reactive oxygen species (ROS) scavenger was shown to attenuate shikonininduced necrosome formation (Park et al., 2013; Lu et al., 2017) . Treatment of shikonin repressed tumor growth of both primary and metastatic osteosarcomas in vivo and resulted in increased tumor necrosis and elevated levels of RIPK1 and RIPK3 in primary tumor tissues (Fu et al., 2013) (Table 1) . Therefore, triggering necroptosis of tumor cells may represent an attractive new strategy for the treatment of cancer, including apoptosis-resistant cancer.
Tumor suppressive activity of necroptosis through control of apoptosis
Strong in vivo evidence for RIPK3-mediated tumor suppression has been provided by the finding that RIPK3 deletion enhances the development of hepatic tumors in a hepatocellular carcinoma (HCC) model induced by the liver parenchymal cell (LPC)-specific deletion of transforming growth factor-β (TGF-β)-activated kinase 1 (Tak1) (Vucur et al., 2013) . Hepatocyte cell death is commonly involved in the progression of liver fibrosis and the HCC that is caused by chronic liver disease. LPC-specific TAK1 knockout (TAK1 LPC-KO ) mice display severe hepatic inflammation as well as spontaneous LPC apoptosis and necrosis (Bettermann et al., 2010 −/− (ablation of TAK1 in LPC together with a full knockout of Rip3) mice exhibited significantly higher inflammatory responses in the liver, suggesting that LPC apoptosis rather than necroptosis contributes to hepatic inflammation (Vucur et al., 2013) . Loss of RIPK3 caused increased apoptosis and proliferation of TAK1-deficient LPC, leading to increased inflammation and carcinogenesis in TAK1
−/− mice (Vucur et al., 2013) . Therefore, manipulation of hepatic apoptosis and necroptosis signaling might represent a new strategy for the prevention and/or treatment of HCC. Recently, it has been shown that the expression of Ripk3 was higher in intrahepatic cholangiocarcinoma (ICC) than in HCC (Seehawer et al., 2018) . The necroptosis-dependent hepatic cytokine microenvironment leads to ICC development, while suppression of necroptosis shifted cell death towards apoptosis and switched ICC to HCC (Seehawer et al., 2018) . These results suggest that the tumor microenvironment determines lineage commitment in liver tumorigenesis.
Tumor suppressive activity of necroptosis through promotion of cell death and differentiation
The tumor suppressive activity of necroptosis is also supported by studies in AML. AML is maintained by a rare population of leukemia-initiating cells (LICs) characterized by inhibition of differentiation and cell death. It has been shown that RIP3 expression is significantly reduced in CD34 + cells from AML patients compared with that in CD34 + cells from healthy donors (Nugues et al., 2014) . Re-expression of RIPK3 in RIP3-null leukemia cell lines induced apoptosis in a smaller proportion of cells, and also activated necroptosis in the presence of the caspase inhibitor, while expression of a kinase dead form of RIPK3 (RIPK3-D161N) in mouse DA1-3b leukemia cells triggered massive apoptosis which was shown to depend on NF-κB activity + T cell anti-tumor immunity. MTX: mitoxantrone; ICD: immunogenic cell death; ATP: adenosine triphosphate; DAMPs: damage-associated molecular patterns; HMGB1: high mobility group box 1; DC: dendritic cell (Nugues et al., 2014) . The induced expression of RIPK3-D161N but not wild-type RIPK3 prolonged the survival of mice after injection of leukemia cells (Nugues et al., 2014) . These results suggest that a decrease in RIPK3 expression in AML cells may contribute to the suppression of both necroptosis and apoptosis.
Moreover, RIPK3 was found to be expressed at reduced levels in samples from patients with FMS-like tyrosine kinase 3 (FLT3)-mutated AML (Höckendorf et al., 2016) (Fig. 3) . Mice lacking RIPK3 showed enhanced survival of FLT3-internal tandem duplication (FLT3-ITD)-transformed hematopoietic stem and progenitor cells (HSPCs) and increased leukemogenesis. Similarly, MLKL-deficient mice accelerated the onset of AML (Höckendorf et al., 2016) . It has been suggested that TNFR-mediated RIPK1/RIPK3-dependent cell death restricts the accumulation of malignant progenitors. In addition, RIPK3-mediated inflammasome activation promoted differentiation of LICs by eliciting interleukin-1β (IL-1β) signaling (Höckendorf et al., 2016) . These results suggest that RIPK3 has tumor-suppressive function(s) in FLT3-mutated AML subtypes through the promotion of necroptosis and the differentiation of LICs.
Necroptosis in anti-tumor immunity
Immunogenic cell death (ICD) can activate host immune responses, especially to malignant tumor cells, to produce strong and persistent anti-cancer immunity (Casares et al., 2005) . Therefore, the necroptosis of cancer cells is becoming increasingly important because of its roles in immunogenicity and in activating the immune system. Studies have shown that induction of cancer cell necroptosis triggers the release of DAMPs to induce dendritic cell (DC) maturation (Yatim et al., 2015; Aaes et al., 2016) (Fig. 2) . It was observed that release of inflammatory mediators such as DAMPs by dying cells is not enough to cause CD8 + T cell cross-priming. Rather, robust crosspriming was found to require RIPK1 signaling and NF-κB-induced intracellular transcription of dying cells (Yatim et al., 2015) . Moreover, vaccination with these necroptotic cancer cells induced cross-priming of T cells and the production of IFN-γ in response to tumor antigen stimulation, and this prevented tumor growth, thus demonstrating the immunogenic nature of necroptotic cancer cells and its association with anti-tumor immunity (Aaes et al., 2016) . Additionally, chemotherapy agents like mitoxantrone (MTX) can reinstate anticancer immunosurveillance by inducing the ICD of tumor cells. Cancer cells undergoing necroptosis induced by MTX exhibited biochemical hallmarks of ICD including calreticulin (CRT) exposure and the release of adenosine triphosphate (ATP) and high mobility group box (HMGB). Deletion of RIPK3 or MLKL in cancer cells repressed chemotherapyinduced ICD and anticancer immune responses in vivo . These results suggest that necroptosis can contribute to ICD signaling and tumor immunogenicity.
Additionally, it was found that RIPK3 reduction in colorectal cancer was associated with accumulation of myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment (Yan et al., 2018) . Reduction of RIPK3 in MDSCs led to upregulation of NF-κB p65 and cyclooxygenase-2 (COX-2) which catalyzed the synthesis of prostaglandin E 2 (PGE 2 ). Addition of PGE 2 inhibited RIPK3 expression, but enhanced the expression of p65 and COX-2 in MDSCs (Yan et al., 2018) . Blockage of COX-2 or PGE 2 receptors by chemical inhibitors reversed the downregulated RIPK3 and the immunosuppressive activity of MDSCs, and reduced the tumorigenesis of colorectal cancer (Yan et al., 2018) . These results suggest that the RIPK3-PGE 2 circuit regulates the infiltration and activity of MDSCs and colorectal cancer carcinogenesis, and thus may be a potential target for the treatment of colorectal cancer.
Necroptosis in tumorigenesis
Necroptosis in macrophage-mediated immune suppression
Although it is believed that the induction of necroptosis in cancer cells contributes to the death of cancer cells and the activation of anti-tumor immunity, necroptosis has been reported to promote tumorigenesis. Chronic inflammation has been recognized as one of the hallmarks of cancer and is known to be involved in tumor progression (Coussens and Werb, 2002) . Given the fact that necroptosis induces the release of DAMPs and inflammatory responses, it is conceivable that necroptosis may stimulate tumor growth. Higher expression levels of RIPK1 and RIPK3 were observed in human pancreatic ductal adenocarcinoma (PDA) than in the surrounding normal pancreas tissue (Seifert et al., 2016) (Fig. 4a) . Deficiency of RIPK3 in mice or inhibition of RIPK1 protected against oncogenic progression of Kras G12D -induced PDA in mice (Seifert et al., 2016) . RIPK1/ RIPK3 signaling-induced chemokine (C-X-C motif) ligand 1 (CXCL1) expression and ligation of Mincle by SAP130 were shown to promote macrophageinduced adaptive immune suppression and therefore accelerated oncogenesis (Seifert et al., 2016) , suggesting that inhibition of RIPK1 or RIPK3 could be beneficial for treating PDA. It is noteworthy that RIPK3-deficient mice were not protected against B16 melanoma or subcutaneously implanted cancer cells with mutant Kras and p53, suggesting that the pro-tumorigenic action of RIPK3 occurs in a cell-type and context-dependent manner. Additionally, it has been shown that RIPK1 was highly expressed in tumorassociated macrophages in the PDA model and suppression of RIPK1 by a selective inhibitor GSK547-induced STAT1-dependent immunogenic reprogramming of tumor-associated macrophages (TAMs), leading to the activation of adaptive immune responses and tumor suppression (Table 1) . Inhibition of RIPK1 synergized with checkpoint receptor (PD-1) and co-stimulatory ligand (ICOS)-based immunotherapies (Table 1) . Unexpectedly, treatment of the RIPK1 inhibitor provided additive protection in RIPK3-deficient mice, suggesting that the tumor-promoting effects of RIPK1 in PDA are independent of RIPK3.
Recently, it has been reported that inhibition of RIPK3 kinase activity by the RIPK3 kinase inhibitor small molecule GSK872 significantly reduced tumors in the small intestine of a spontaneous intestinal tumor model (Apc Min/+ mice) (Jayakumar and Bothwell, 2019) (Fig. 4b, Table 1 ). Intermediate MDSCs (I-MDSCs) were significantly decreased in the GSK872-treated Apc Min/+ mice, while monocytic MDSCs (M-MDSCs) and macrophages were moderately reduced. Injection of I-MDSC enhanced tumor growth and increased the number of CD4 + IL-17 + cells in a mouse MC38 colon cancer model; in contrast, these phenotypes were suppressed by treatment with GSK872 (Jayakumar and Bothwell, 2019) . Although these results suggest a role for RIPK3 in the promotion of intestinal tumors by regulating I-MDSCs-mediated expansion of IL-17-producing T cells, further studies will be required to dissect any necroptosis-dependent or necroptosisindependent functions of RIPK3 in the tumorigenesis of Apc Min/+ mice, for example by using genetic deletion of necroptosis components. 
Other mechanisms for necroptosis-mediated tumor promotion
There was also evidence showing that deletion of RIPK1, RIPK3, or MLKL in human breast cancer MDA-MB-231 cells repressed xenograft tumor growth in nude mice (Liu et al., 2016) . Similarly, deletion of RIPK3 in human 4T1 breast cancer reduced tumor growth in syngeneic Balb/C mice (Liu et al., 2016) . Moreover, the MLKL inhibitor necrosulfonamide (NSA) inhibited growth of MDA-MB-231 xenograft tumors (Liu et al., 2016) (Table 1) . Although previous studies have shown that necroptosis promotes cancer cell death and therefore benefits cancer treatment, the results of Liu et al. (2016) suggest the apparent tumor-promoting properties of necroptosis components in these cancer cells. p65/RelA phosphorylation, a marker indicating NF-κB activation, was reduced in RIPK3 knockout cells, while p65/RelA phosphorylation was not changed in RIPK1 or MLKL knockout cells. It is believed that aberrant activation of NF-κB is observed in most cancers and increases tumor proliferation and tumor-related inflammation. Further investigations are needed to confirm the impact of NF-κB signaling on RIPK3-mediated tumor progression and to delineate any mechanism(s) underlying tumorigenesis as driven by necroptosis components.
In addition, it has been shown that RIPK3 is more highly expressed in the M4 and M5 subtypes of AML (Xin et al., 2017) (Fig. 3) . Knockout of RIPK1 or RIPK3 in MA9-AML cells sensitized cells to IFN-γ-induced differentiation and repressed leukemia development (Xin et al., 2017) . Treatment with the RIPK1 inhibitor Nec-1 combined with IFN-γ significantly enhanced human primary AML cell differentiation and attenuated clonogenic capacity, suggesting that blockage of RIPK1/RIPK3 signaling may be a new approach for treatment of several subtypes of AML in combination with IFN-γ (Xin et al., 2017) (Table 1) . However, such a negative role for RIPK1/ RIPK3 in AML cell differentiation is inconsistent with the previous observation that RIPK3 signaling promotes LIC cell death and differentiation in FLT3-IDT-induced AML (Höckendorf et al., 2016) . The role of RIPK1/RIPK3 signaling in AML pathogenesis thus appears to vary among the different subtypes of AML, so the therapeutic potential of strategies targeting necroptosis must be carefully evaluated in relevant mouse models and in large and diverse patient cohorts.
Necroptosis in the promotion of metastasis
Metastasis is the major cause of cancer-related death and is understood to be a complex process resulting in the spread of cancer cells to distant parts of the body through the circulatory system. It has been shown that in vitro co-culture of tumor cells with endothelial cells induces endothelial cell death via RIPK1-RIPK3-MLKL-dependent necroptosis (Strilic et al., 2016) . In lung metastasis models of B16 and LLC1 in vivo, endothelium-specific caspase 8 deficiency could inhibit apoptosis and further promote necroptosis, which eventually aggravated lung metastasis (Strilic et al., 2016) . Endothelial cell-specific deletion of RIPK3, the complete loss of MLKL, or necrosatin-1 treatment was each shown to reduce tumor cell-induced endothelial necroptosis as well as tumor cell extravasation and metastasis. This endothelial necroptosis was induced via the activation of death receptor 6 (DR6) in endothelial cells upon exposure to amyloid precursor protein (APP) in tumor cells. These results suggest a role for necroptosis in the disruption of vascular endothelial barriers for promoting metastasis (Strilic et al., 2016) (Fig. 5a) . Recently, it has been reported that endothelial TGF-β-activated kinase 1 (TAK1) acts as a negative regulator of endothelial necroptosis and metastasis (Yang et al., 2019) . TAK1 deletion resulted in increased expression of RIPK3 in endothelial cells and enhanced both necroptosis of endothelial cells and metastasis of tumor cells (Yang et al., 2019) . Deficiency of RIPK3 effectively inhibited tumor metastasis in epithelium-specific TAK1 knockout mice (Yang et al., 2019) . These results support the idea that sustained TAK1 signaling is required for controlling the low levels of necroptosis components in endothelial cells.
Nevertheless, there is also evidence showing that loss of RIPK3 kinase activity or loss of MLKL had no significant effect on metastasis, although the complete loss of RIPK3 or loss of RIPK1 kinase activity was confirmed to suppress tumor cell extravasation and metastasis (Hänggi et al., 2017) . Cell death in primary endothelial cells upon co-incubation of tumor cells was shown to be independent of RIPK3 or MLKL. It was found that RIPK1 kinase activity and RIPK3 promote vascular endothelial growth factor (VEGF)-dependent activation of p38/HSP27 mitogenactivated protein (MAP) kinase signaling axis to facilitate vascular permeability and vessel sprouting (Hänggi et al., 2017) (Fig. 5b) . These results suggest a necroptosis-independent function for RIPK1/RIPK3 in vascular permeability that may contribute to tumor metastasis. Although further studies are needed to elucidate the precise molecular mechanism through which RIPK1 and RIPK3 may mediate tumor cell extravasation, these observations reveal that RIPK1 and RIPK3 can be viewed as potential targets for developing therapeutic interventions against metastasis. Indeed, studies showed that blockage of RIPK1 kinase activity by Nec-1 or a different RIPK1 inhibitor significantly reduced tumor metastasis in vivo (Strilic et al., 2016; Li et al., 2018) (Table 1) .
In addition to endothelial cell necroptosis, necroptosis of tumor cells was recently found to promote tumor metastasis (Jiao et al., 2018) . The phosphorylation of MLKL, the marker of necroptosis activation, was detected in areas of tumor necrosis in both human breast cancer samples and mouse breast cancer models, including a spontaneous breast cancer model (MMTV-PyMT mice) and syngeneic breast cancer model (Jiao et al., 2018) . Deletion of MLKL in mouse MVT-1 breast cancer cells greatly reduced breast cancer metastasis to the lung (Jiao et al., 2018) . These results provide strong evidence suggesting that tumor cell necroptosis occurs during tumor development and participates in the pathogenesis of cancer metastasis (Fig. 5c ).
Concluding remarks
Necroptosis is now recognized as a major form of regulated cell death. It is mediated by RIPK1/ RIPK3 activation, followed by MLKL phosphorylation, oligomerization, and membrane translocation, and finally membrane disruption. Necroptosis is becoming increasingly attractive as a field of study given its implications in the pathogenesis of inflammatory diseases, degenerative diseases, and cancer. As a highly inflammatory form of regulated cell death, necroptosis has very complicated roles in cancer initiation, development, and metastasis. Although the necroptosis field has developed rapidly in recent years, it also faces many challenges. For example, it remains unclear how the action of MLKL links to membrane leakage. Given that RIPK3 expression is restricted in most tumor cells, we do not yet understand the action of RIPK3 in other cells including immune cells and stromal cells in the tumor microenvironment. RIP kinase necroptosis components are now understood to mount inflammatory responses by causing necroptosis or directly regulating inflammatory signaling pathways, but it is not yet known if RIPK1 and/or RIPK3 activate the necroptosis pathway or/and the immune responses to affect tumorigenesis. What are the regulatory mechanisms of necroptosis in different types of cancer? In addition, it is not clear whether there is a regulatory mechanism that controls metastasis through necroptosis at different stages of cancer progression. Further precise characterization of necroptosis, using specific biomarkers in animal models and human pathological samples, will be critical for the validation of the significance of necroptosis in different types of cancer. Exploring these questions will almost certainly contribute to a deeper basic biological understanding of the mechanisms of necroptosis and its action in the regulation of tumorigenesis and should provide major actionable insights to guide the development of novel therapeutic strategies for cancer that target necroptosis components.
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